Business context and reporting period
EDAP TMS S.A. filed this Form 20-F on April 30, 2018, reporting on the fiscal year ended December 31, 2017, with comparative annual results. This is an annual filing, not a standalone fourth-quarter report; the filing text does not provide a clear set of Q4-only financial results. The French medical-device company develops and sells HIFU systems for prostate treatment and extracorporeal shockwave lithotripsy (ESWL) equipment, and distributes other urology products. Figures below are in euros unless otherwise noted; financial statements use U.S. GAAP.
Key financial results
| Metric | 2017 | 2016 |
|---|---|---|
| Total revenue | €35.746m | €35.611m |
| Gross profit / gross margin | €14.808m / 41.5% | €16.411m / 46.1% |
| Operating income (loss) | (€2.027m) | €0.392m |
| Net income (loss) | (€0.681m) | €3.842m |
| Operating cash flow | (€3.059m) | €1.209m |
| Cash and cash equivalents at year-end | €20.004m | €21.989m |
| Total current assets / current liabilities | €39.574m / €16.134m | €40.502m / €15.010m |
Revenue was nearly flat year over year. Sales of goods were €22.580m, RPPs and leases €5.095m, and spare parts and services €8.011m. R&D expense was €3.881m, selling and marketing expense €9.526m, and general and administrative expense €3.428m.
Material changes versus 2016
- HIFU revenue fell 31.2% to €9.5m. Device sales declined to €2.3m, with two Ablatherm and three Focal One units sold, compared with 14 HIFU units in 2016. Treatment-driven revenue increased 12.9% to €6.1m, and HIFU maintenance revenue rose to €1.1m.
- UDS revenue increased 20.4% to €26.2m. ESWL device sales rose to €15.1m, with 40 units sold versus 36 in 2016; related spare-parts, supplies and service revenue grew 16.1% to €11.1m.
- Gross margin fell from 46.1% to 41.5%, reflecting lower HIFU revenue and a less favorable division mix; HIFU margins are higher than UDS margins. Operating expenses rose 5.1% to €16.8m.
- The company moved from operating profit and net income in 2016 to an operating loss and net loss in 2017. Net foreign-exchange loss was €0.909m, versus a €0.103m gain in 2016.
- Operating cash flow turned negative, and cash declined by €1.985m during the year. Investing activities used €2.032m; financing activities provided €2.871m.
Debt, liquidity and unusual items
At year-end, short-term borrowings were €2.718m and long-term debt was €1.217m, including €0.383m current and €0.834m non-current. Capital lease obligations totaled €0.783m. The company also reported €0.840m of current warrant liabilities. Cash was €20.004m, with no short-term investments. Contractual obligations included €2.581m of operating leases.
Financial income, net was €2.643m in 2017, materially offsetting the operating loss. The financial-statement note attributes €2.044m to changes in warrant fair value and €0.625m to warrants exercised or forfeited; the narrative discussion describes the warrant fair-value income differently. Investors should verify the detailed reconciliation. The filing identifies no off-balance-sheet arrangements other than those described in the notes.
Guidance, outlook, risks and contingencies
- Management expected 2018 European R&D spending to rise to approximately 13% of revenue and selling and marketing expense to continue increasing as the company expands. It provided no specific revenue or profitability guidance.
- Focal One’s resubmitted U.S. 510(k) application remained under FDA review. Ablatherm Fusion received FDA clearance in October 2017; Ablatherm had prior U.S. clearance for prostate-tissue ablation. U.S. reimbursement and wider HIFU adoption remained uncertain.
- Management described the ESWL market as mature, with ongoing price competition, and highlighted reliance on HIFU acceptance and product approvals for growth. Other stated risks include clinical and regulatory delays, reimbursement changes, dependence on a single manufacturing site and certain single-source suppliers, foreign-exchange exposure, and fluctuating hospital demand.
- The company reported a material weakness in internal control over financial reporting: insufficient segregation of duties and review documentation in the consolidation process because of a small finance team. Management and the auditor concluded controls were not effective at December 31, 2017; neither identified a resulting material misstatement or restatement. Remediation plans included hiring for consolidation or using a third party temporarily.
- The auditor gave an unqualified opinion on the financial statements, but an adverse opinion on the effectiveness of internal control over financial reporting. A March 2018 FDA inspection resulted in one Form 483 observation concerning management-review procedures; the filing says no further action was indicated at that time and the issue was being addressed.
- Outstanding warrants and options present potential dilution; the filing cites up to 5,870,784 ADSs issuable as of April 2, 2018, approximately 20.3% of issued and outstanding share capital. No dividends were paid for 2013–2016, and management did not anticipate a 2017 dividend.
Most important facts to verify
- Reconcile the warrant-related financial income disclosures and assess how much of reported earnings was non-cash or non-operating.
- Track HIFU device placements, treatment-driven revenue, Focal One FDA review, and reimbursement progress against the sharp 2017 decline in HIFU equipment sales.
- Monitor whether UDS growth and margins can offset continued HIFU investment and the lower consolidated gross margin.
- Assess cash conversion, working-capital needs, debt and lease payments, and liquidity if operating cash flow remains negative.
- Confirm timely remediation of the consolidation-control material weakness and review the status of the FDA Form 483 observation.